FABRICATION AND OPTIMIZATION OF NOVEL GLIPIZIDE SUSTAINED RELEASE MATRICES FOR SOLUBILITY AND DISSOLUTION ENHANCEMENT BY SOLID DISPERSION THROUGH HYDROPHILLIC CARRIERS
The present research work was to improve the dissolution rate of glipizide which belongs to BCS II drug by enhancing its aqueous solubility using different hydrophilic carriers like PEG 6000 and hydroxypropyl methylcellulose E15 (HPMC E15). The solid dispersion was embedded into the matrix of polymers to sustain the release pattern of drug. The various solid dispersion formulations were prepared by employing fusion method using different carriers. Further solid dispersion formulations were subjected to different in-vitro evaluation tests for solubility, drug content uniformity, drug-polymer interaction, DSC study and in-vitro drug release study. Tablets were prepared by direct compression method and evaluated for various physical parameters. A direct compression methodÂ using response surface methodology, followed by optimization of theÂ evaluatedÂ parametersÂ was employedÂ to getÂ the final optimized formulation. The results of drug content uniformity showed the uniform dispersion of glipizide in solid dispersion formulations. The DSC endothermic peak at 216.08Â°C due to glipizide was partially and completely disappeared in solid dispersion formulation indicating that drug was completely dispersed in formulations. In-vitro drug release showed 80.35% in 60 minutes for the best solid dispersion formulation S3 (ratio 1:3). Among all the formulations, F4 shows 92.87% better sustained release at the end of 12 hrs. The release co-efficient values â€˜nâ€™ (Ë‚0.5) indicated that the drug release followed fickian diffusion mechanism based on formulation factors. The stability studies were carried out according to ICH guideline and result found of selected formulation was stable.
Keywords: Glipizide, Solid dispersion, Xanthan gum, Matrices
2. Patil PD, Bakliwal SR, Gujarathi NA, Rane BR, Pawar SP, Kapoor B, Solid dispersion: an evolutionary approach for solubility enhancement of poorly water soluble drugs, Pharma Science Monitor, 2013; 4(1):3683-3709.
3. Bhirud Y, Phalak H. Advances in solid dispersion technology and its applications in the development of solid dosage forms. Journal of Drug Delivery and Therapeutics, 2016; 6(6):40-47. doi:10.22270/jddt.v6i6.1316.
4. Jamzad S, Fassihi R, Development of controlled release low dose class II drug-glipizide, Int J Pharm, 2006; 312:24-32.
5. Dalvi P, Gerange A, Ingale P, Solid dispersion: strategy to enhance solubility. Journal of Drug Delivery and Therapeutics, 2015; 5(2):20-28. doi:10.22270/jddt.v5i2.1060
6. Pahwa R, Bohra P, Sharma PC, Kumar V, Dureja H, Glipizide: some analytical, clinical and therapeutic vistas, Int. J. Chem. Sci., 2010; 8(1):59-80.
7. Patel JK, Patel RP, Amin AF, Patel MM, Formulation and evaluation of glipizide microspheres, AAPS Pharm Sci Tech, 2005; 6:49-55.
8. Rodriguez L, Caputo O, Cini M, Cavallari C, Grecchi R, In-vitro release of theophylline from directly-compressed matrices containing methacrylic acid copolymers and/or dicalcium phosphate dehydrate, Ill Farmaco, 1993; 48:1597-604.
9. Sareen S, George M, Lincy J, Improvement in solubility of poor water-soluble drugs by solid dispersion, Int J Pharm Investig, 2012; 2(1):12â€“17.
10. Raymond CR, Paul JS, Paul JW, Ray R, Paul S, Hand book of pharmaceutical excipients. (4th edn), Science and Practice, Royal Pharmaceutical Society of Great Britain, London, 2003; UK 447-450.
11. Frizon F, Eloy J, Donaduzzi C, Dissolution rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersion by solvent methods. Powder Technology, 2013; 235:532-539.
12. Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. 3rd ed. Mumbai: Varghese Publishing House; 1991. P. 297-300.
13. Sareen S, George M, Lincy J, Improvement in solubility of poor water-soluble drugs by solid dispersion, Int J Pharm Investig, 2012; 2(1):12â€“17.
14. Shaikh K, Dissolution and stability enhancement of poorly water soluble drug - lovastatin by preparing solid dispersions, Asian Journal of Biomedical and Pharmaceutical Sciences, 2011; 1(4):24-31.
15. Hindustan AA, Sreeramula J, Hima Bindu V, Kumar CS , A formulation and evaluation of once daily sustained release aceclofenac prosophis juliflora gum matrix tablets, International Journal of Pharmaceutical Sciences Review and Research, 2010; 1(2):23-28.
16. Shanker G, Kumar CK, Gonugunta CS, Kumar BV, Veera reddy PR, Formulation and evaluation of bioadhesive buccal drug delivery of tizanidine hydrochloride tablets, AAPS Pharm Sci Tech, 2009; 10(2):530-539.
17. Liu Q, Fassihi R, Zero order delivery of highly soluble, low dose drug alfuzosin hydrochloride via gastro retentive systemâ€, International Journal of Pharmaceutics, 2008; 348(1-2):27-34.
18. Radhika PR, Pal TK, Sivakumar T, Formulation and evaluation of sustained release matrix tablets of glipizide, Iranian Journal of Pharmaceutical Sciences, 2009; 5(4):205-214.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).